Genprex, Inc. Secures Israeli Patent for REQORSA® Gene Therapy in Combination with PD-1 Antibodies for Cancer Treatment

Key Highlights from the Report

• Patent Granted in Israel: On April 30, 2026, Genprex, Inc. (“Genprex” or the “Company”) announced it has been granted a patent by the Israel Patent Office (ILPO) for the use of REQORSA® Gene Therapy (quaratusugene ozeplasmid) in combination with PD-1 antibodies for the treatment of cancer.
• Strategic Expansion of Intellectual Property: This new patent further extends Genprex’s intellectual property portfolio, adding to its coverage in major global markets and reinforcing the scientific innovation behind REQORSA®.
• Potential Impact on Cancer Treatment: The patent covers the use of REQORSA® in combination with PD-1 antibodies, a class of immunotherapy drugs that have transformed cancer treatment. This combination approach is at the forefront of oncology research and may offer new therapeutic options to patients.

Details Investors and Shareholders Need to Know

• Significance of the Patent: The newly granted patent in Israel is a substantial addition to Genprex’s intellectual property estate. Patents are critical assets for biotech companies, as they protect proprietary technologies and can enhance long-term competitive positioning.
• Potential Market and Commercial Implications: Given that PD-1 antibodies (such as pembrolizumab and nivolumab) are widely used immunotherapies in oncology, Genprex’s ability to combine its gene therapy with these agents could expand its addressable market, attract commercial partnerships, and potentially accelerate clinical adoption if proven effective in trials.
• Global IP Strengthening: The press release emphasizes that this is part of a global IP strategy, indicating Genprex’s intent to secure broad international protection for REQORSA®-based therapies. This is particularly relevant for future commercialization, licensing discussions, and global regulatory submissions.
• Forward-Looking Risks: The company cautions that forward-looking statements are subject to risks and uncertainties. These include, but are not limited to, the advancement and successful completion of clinical trials for REQORSA®, obtaining regulatory approvals, manufacturing and commercialization capabilities, maintaining Nasdaq listing compliance, and securing necessary funding to continue operations.
• Corporate Leadership: The report is signed by Ryan Confer, who serves as both Chief Executive Officer and Chief Financial Officer, indicating a streamlined leadership structure at Genprex.

Potentially Price-Sensitive Information

• Intellectual Property Milestone: Securing a new patent in Israel for a key combination therapy could be seen as a positive development by investors, strengthening Genprex’s competitive position and possibly enhancing its attractiveness for future partnerships or acquisitions.
• Pipeline Progress: The patent grant is a potential catalyst for the company’s stock, as it reinforces the value of REQORSA® and its potential utility in combination with PD-1 inhibitors, a high-profile area in oncology.
• Ongoing Regulatory and Financial Considerations: Investors should monitor the company’s progress in clinical trials, regulatory filings, and ongoing efforts to maintain Nasdaq listing and secure additional capital.

Additional Context

• Genprex is a clinical-stage gene therapy company focused on developing gene-based therapies for cancer and diabetes.
• REQORSA® is the company’s lead product candidate, with ongoing studies targeting non-small cell lung cancer (NSCLC) and other tumor types, especially in combination with checkpoint inhibitors like PD-1 antibodies.
• The company’s business address is 1601 Trinity Street, Bldg. B, Suite 3.322, Austin, TX 78712, and it is listed on the Nasdaq Capital Market under the ticker symbol GNPX.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Forward-looking statements contained herein are based on current expectations and are subject to risks, including those detailed in Genprex’s filings with the Securities and Exchange Commission. Investors should conduct their own due diligence and consult with a qualified financial advisor before making investment decisions. The information provided may not reflect subsequent events or changes in circumstances.

View Genprex, Inc. Historical chart here